NCT06461988View on ClinicalTrials.gov

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 5, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Multiple MyelomaPost Stem Cell Transplant
Interventions
DRUG

Talquetamab

"Talquetamab Step up dosing:~C1D1: 10 mcg/kg C1D3: 60 mcg/kg C1D5: 400 mcg/kg C1D15: 800 mcg/kg~Talquetamab 800 mg/kg SC Q4W in 28-day cycle for Cycles 2-13"

DRUG

Talquetamab and Lenalidomide

Lenalidomide 10 mg, 3 weeks on 1 week off, until PD/ intolerance, C2-13 (Lenalidomide 5 mg for creatinine clearance 30-60 ml/min)

Trial Locations (1)

94304

RECRUITING

Stanford University, Palo Alto

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

Stanford University

OTHER

NCT06461988 - Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma | Biotech Hunter | Biotech Hunter